Pharma major Glenmark Generics today commenced marketing and distribution of Cyclobenzaprine Hydrochloride tablets in the US market.
Cyclobenzaprine Hydrochloride tablets are a generic version of McNeil Pediatrics' Flexeril tablets, used for treatment of muscle spasms.
Glenmark has launched the drug in collaboration with InvaGen Pharmaceuticals. While Glenmark will market and distribute the tablets, InvaGen Pharmaceuticals will be responsible for their manufacture and supply.
Profits from the sale of the drug will be shared between Glenmark and InvaGen.
Overall, generic market sales of the product totalled approximately Rs 169.2 crore in the last fiscal.
Glenmark's current portfolio consists of 58 products authorised for distribution in the US market place. The company has over 50 ANDAs awaiting the green signal from the US Food and Drug Administration.
